###### Strengths and limitations of this study

-   First study concerning patients with inherited peripheral neuropathies in South of France.

-   New single-nucleotide variation mutations important for the scientific and medical community.

-   New copy number variations detected by the analysis of next-generation sequencing data.

-   Lack of power (123 patients).

-   Lack of functional validation of variants of unknown significance.

Introduction {#s1}
============

We defined three main categories of inherited peripheral neuropathy (IPN): hereditary motor and sensory neuropathy, more commonly called Charcot-Marie-Tooth disease (CMT), hereditary sensory and autonomic neuropathy (HSAN) and distal hereditary motor neuropathy (dHMN).

With a prevalence of 1/2500,[@R1] CMT is one of the most frequent cause of neurological disability, characterised by extensive phenotypic and genetic heterogeneity, with all modes of inheritance described. Based on histopathological and electrophysiological criteria, CMT are further categorised into CMT type 1, or demyelinating type (CMT1/HMSN1), and CMT type 2, or axonal type (CMT2/HMSN2). While CMT type 1 is associated with reduced nerve conduction velocities, correlated to decreased myelination of the peripheral nerves, CMT type 2 is characterised by decreased amplitudes of motor and sensory nerve action potentials, related to primarily axonal loss in the peripheral nerve fibres. Patients with both signs of demyelination and axonal degeneration are diagnosed with intermediate CMT, although there is much controversy about the exact definition of intermediate CMT.[@R2]

The disease usually starts in childhood or the teenage years and it generally aggravates slowly and progressively. Clinically, most patients present distal motor and sensory weakness associated with feet deformations (most frequently pes cavus) and sometimes other skeletal deformations such as scoliosis. Additional manifestations may exist such as deafness, optic atrophy or pyramidal signs. The disease is characterised by high clinical heterogeneity, both intrafamilial and interfamilial. Concerning the latter, the severity of the disease is highly variable, ranging from almost asymptomatic adult patients to severely disabled children.

Genetically, the disease is also highly heterogeneous, with more than 100 defective genes reported today.[@R3] In our laboratory, before the advent of next-generation sequencing (NGS), the screening strategy was based on Sanger sequencing of candidate genes, except for the *PMP22* duplication, following the recommendations of the French Network of Molecular Diagnosis Laboratories for NeuroMuscular Diseases (<http://www.anpgm.fr/>), who had set up decision trees based on data from the literature. The screening of one specific gene was determined by clinical, genealogical and electrophysiological criteria. For all patients, the 1.5 Mb duplication at chromosome 17p11.2 encompassing the *PMP22* gene, the most frequent cause of CMT, was first achieved by multiplex ligation-dependent probe amplification (MLPA). In negative cases, a subsequent gene by gene sequential screening was carried out, and the screened genes were different whether the patient presented demyelinating or axonal CMT. For patients with autosomal-dominant demyelinating CMT (CMT1), the screening of *GJB1*, the gene encoding connexin 32, was then carried out through Sanger sequencing, followed by the sequential screening of: *MPZ*, *LITAF*/*SIMPLE*, *NEFL*, *GDAP1* and *EGR2*. In autosomal-dominant axonal CMT (CMT2), the patients were subjected to Sanger sequencing screening of the following genes: *GJB1*, *MFN2* (especially if the patient show pyramidal signs or optic atrophy), then *MPZ* and *NEFL*.

In the last few years, the molecular diagnosis improved with the advent of NGS, which is now the strategy used in routine in our laboratory, in patients negative for the *PMP22* duplication. The list of genes involved in IPNs is constantly rising, and is now above 100.

Our objective is to compare the diagnostic yield of a targeted NGS strategy (panel of 81 IPN/CMT genes) with the previous gene by gene Sanger sequencing strategy, by comparing the results of NGS in a cohort of 123 patients and the results of Sanger sequencing in a group of 56 patients. We compare the molecular diagnostic resolution rates between demyelinating and axonal CMT forms. We also report on new likely pathogenic variants, not yet described in the literature, and we present the most frequently mutated genes in our group. Finally, we describe two candidate copy number variations (CNVs), identified from the NGS data.

Materials and methods {#s2}
=====================

Clinical data {#s2a}
-------------

For NGS screening, we have prospectively included 123 index cases affected with hereditary motor and sensory neuropathy, dHMN and HSAN, seen in consultation in the Neuromuscular Disease Reference Center, since 2015.

For Sanger sequencing, we have studied a retrospective cohort of 56 patients seen in consultation between 2012 and 2014.

Patient and public involvement {#s3}
==============================

Patients and/or public were involved neither in the design of this study protocol nor in the development of the research question. Patients and/or public will not be involved in the recruitment process. The results of this study will be presented at the next FILNEMUS conference.

Statistical analysis {#s4}
====================

We have compared the targeted NGS strategy to the previous gene analysis by Sanger sequencing on a retrospective cohort of 56 patients seen between 2012 and 2014 using a two-failed Fisher's exact test.

Genetic studies {#s5}
===============

Samples {#s5a}
-------

A written and signed approval has been collected from the patients in accordance with French recommendations as well as in agreement with the local ethics committee rules.

DNA was extracted from peripheral blood using standard procedures. DNAs were prepared and stored at the accredited Biological Resource Centre (CRB TAC component (NF S96-900 and ISO 9001 v2015 Certification) Department of Medical Genetics, Timone Hospital of Marseille (APHM). All DNAs belong to a biological sample collection declared to the French Ministry of Health (declaration number DC-2008--429) whose use for research purposes was authorised by the French ministry of Health (authorisation number AC-2011--1312 and AC-2017--2986).

All patients were searched for the *PMP22* duplication before including them in the NGS analysis protocol. To test for the PMP22 duplication, we used an MLPA protocol (MRC-Holland) following the manufacturer's recommendations.

Next-generation sequencing {#s6}
==========================

Library preparation and sequencing {#s6a}
----------------------------------

Libraries were prepared using the ClearSeq Inherited Disease Panel from Agilent (Santa Clara, California, USA), which enables the capturing of 2742 genes known to cause inherited disorders. The coding regions and flanking intronic regions of the 2742 genes were enriched, in solution, using the SureSelect Target Enrichment System from Agilent (Santa Clara, California, USA), following the manufacturer recommendations.

For sequencing, we used the Ion Proton platform (Thermo Fisher Scientific, USA).

Computational analysis {#s6b}
----------------------

After capturing enrichment and sequencing, raw data were converted to Fastq files, aligned to the reference sequence of the human genome (University of California Santa Cruz (UCSC) hg19/GRCh37), and annotated, using the Ion Proton platform integrated workflow (Thermo Fisher Scientific, USA). The obtained variant call format and binary alignment map (BAM) files were used for variant search as described below.

In a diagnosis settings, we realised a targeted analysis of the NGS data, focusing on a list of 81 IPN genes (see online [supplementary table 1](#SP1){ref-type="supplementary-material"}). The data were filtered, using an 'in-house' tool for variant annotation and Filtering Variant Annotation and Filter Tool (<https://varaft.eu/download.php>)[@R5]: (1) variants with allele frequencies \<1% in the Exome Aggregation Consortium (ExAC) data set (<http://exac.broadinstitute.org/>) were removed, (2) the remaining variants were filtered based on their type and genomic localisation, thus, synonymous, intronic, variants in intergenic, 3' and 5' Untranslated Region (UTR) regions were discarded. In order to predict the deleterious effect of the identified sequence variations, different bioinformatics tools were applied, such as MutationTaster (<http://www.mutationtaster.org/>),[@R6] Sorting Intolerant From Tolerant (SIFT) (<http://sift.bii.a-star.edu.sg/>),[@R7] PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>)[@R8] and Universal Mutation Database (UMD) predictor (<http://umd-predictor.eu/>).[@R9]
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In order to check whether variants had already been inventoried and classified, we looked up in Online Mendelian Inheritance in Man (OMIM) (<https://www.ncbi.nlm.nih.gov/omim>), ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) and HGMD (<http://www.hgmd.cf.ac.uk>). Finally, thanks to the American College of Medical Genetics and Genomics (ACMG) recommendations (Richards classification, 2015)[@R10] and to in silico analyses, we classified these variants into five categories: pathogenic, probably pathogenic, variant of unknown significance (VUS), probably benign and benign.

Copy number variations {#s6c}
----------------------

In order to identify CNV in our cohort, we used ExomeDepth.[@R11] This tool uses the BAM files from the NGS sequencing run as well as the bed file containing the target regions to be studied (81 genes, see online [supplementary table 1](#SP1){ref-type="supplementary-material"}). This tool allows to compare the reading depth of our patients' BAM files, to a set of reference samples, in order to eliminate the capturing and sequencing mistakes. Variations in the depth of sequencing are linearly correlated to the variation of the copy number. Deletions and duplications found by ExomeDepth were confirmed by a quantitative (Q)-PCR (Applied Biosystems ViiA 7 Real-Time PCR System).[@R12] The CNV analysis of *TFG* and *FGD4* genes was performed using a commercial kit TaqMan Copy Number Assays (HS00918833-CN) by real-time PCR multiplex. Each analysis was done in triplicate.

Sanger sequencing {#s6d}
-----------------

Variants found by NGS were confirmed and segregated by Sanger sequencing. In our previous sequential gene by gene analysis, the complete coding sequence of genes were PCR amplified and sequenced by fluorescent Sanger sequencing.

In both situations, genomic and cDNA sequences of the genes were obtained from the UCSC Genomic Browser, February 2009, human reference sequence (GRCh37). Primers used for PCR amplification were designed using Primer3 software (<http://frodo.wi.mit.edu>) to amplify the region surrounding the candidate DNA variations.

PCR products were purified by mixing with a volume ratio (1/8) (36 uL) of AMPure beads (Beckman Coulter, USA) according to the manufacturer's instructions and both strands were sequenced using the Big Dye Terminator V.1.1 Cycle Sequencing Kit (Applied Biosystems). Sequence reactions were purified on Sephadex G50 (Amersham Pharmacia Biotech, Foster City, California, USA) and capillary electrophoresis was performed on Genetic Analyser ABI3500XL (Life Technologies, USA). Electrophoregrams were analysed on the Sequence Analysis Software V.5.2 (Applied Biosystems) and aligned with the reference sequence using Sequencher V.5.4.6.

Results {#s7}
=======

Among the 123 patients, 28 (23%) had CMT type 1, 64 (52%) had CMT type 2, 11 (9%) had dHMN, 9 (7%) had HSAN, 8 (6,5%) had intermediary CMT and 3 (2,5%) had CMT without clinical information. [Table 1](#T1){ref-type="table"} sums up the phenotypic features of the patients for whom we identified a mutation or a candidate variant ([table 1A](#T1){ref-type="table"} for patients with CMT1, [table 1B](#T2){ref-type="table"} for patients with CMT2 and [table 1C](#T3){ref-type="table"} for patients with others forms of IPN).

###### 

Clinical and electrophysiological features from 19 IPN index patients with CMT1, for whom a candidate variant was identified

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Disease     Gene                   Gender   Age at onset   Deep tendon reflexes   Foot deformities   Muscular weakness and wasting of distal muscles   Sensory loss   Other clinical signs         Median nerve motor MNCV (m/s)   Median nerve distal CMAP (mV)   Nerve biopsy
  --------- ----------- ---------------------- -------- -------------- ---------------------- ------------------ ------------------------------------------------- -------------- ---------------------------- ------------------------------- ------------------------------- --------------
  2         CMT1 AR     *SH3TC2*               M        3 years        −                      NA                 \+                                                \+                                          NA                              NA                              --

  3         CMT 1 SPO   *GJB1*                 M        19 years       −                      \+                 \+                                                −              Scoliosis                    36                              NR                              --

  5         CMT1 SPO    *INF2*                 F        6 years        −                      \+                 \+                                                \+             Deafness+\                   NA                              NA                              --
                                                                                                                                                                                  diaphragmatic palsy                                                                          

  9         CMT1 AD     *DNM2*                 M        22 years       −                      \+                 \+                                                −                                           35                              NA                              --

  10        CMT1 AD     *NEFL*                 F        60 years       NA                     \+                 \+                                                \+             Cerebellar ataxia            NA                              NA                              NA

  12        CMT1 AD     *LMNA*                 F        22 months      −                      −                  −                                                 −                                           NR\*                            NR\*                            --

  14        CMT1 AR     *SH3TC2*               M        44 years       −                      \+                 \+                                                \+                                          21                              NA                              --

  15        CMT1 AD     *LITAF/SIMPLE*         M        23 years       −                      \+                 −                                                 \+                                          23                              5.7                             --

  16        CMT1 AD     *GJB1*                 F        15 years       −                      NA                 \+                                                \+                                          36                              NA                              Onion bulbs

  17        CMT1 AR     *GDAP1*                F        8 months       −                      \+                 \+                                                −              Kyphosis                     39                              1.02                            --

  18        CMT1 AD     *AARS*                 M        43 years       −                      \+                 \+                                                \+                                          25                              NA                              --

  20        CMT1 AR     *FIG4*                 F        12 years       −                      \+                 \+                                                −                                           26                              3.6                             NA

  21        CMT1 AD     *TRPV4 LRSAM1 KIF1B*   M        10 years       −                      \+                 \+                                                \+             Scoliosis                    25                              NA                              NA

  28        CMT1 AD     *LITAF DCTN1*          F        20 months      \+                     \+                 \+                                                −                                           33                              3.9                             NA

  32        CMT1 SPO    *NEFL*                 M        2 years        −                      \+                 \+                                                −              Sensorineural hearing loss   29                              4.42                            --

  34        CMT SPO     *KIF1B*                F        2.5 years      −                      \+                 −                                                 −                                           NA                              NA                              --

  41        CMT1 AR     *SH3TC2*               F        3 years        −                      \+                 −                                                 −              Scoliosis                    33                              1.04                            --

  45        CMT1 AD     *INF2*                 F        3 years        −                      \+                 −                                                 −                                           21                              5.2                             --

  47        CMT1 AR     *HK1*                  M        8 years        −                      \+                 \+                                                \+             Scoliosis                    22                              NA                              --
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*ENMG show chronic denervation.

+, presence; −, absence; AD, autosomal-dominant; AR, autosomal recessive; CMAP, compound muscle action potential; CMT1, Charcot-Marie-Tooth disease type 1; ENMG, Electroneuromyogramm; F, female; IPN, inherited peripheral neuropathy; MNCV, motor nerve conduction velocity; NA, not available; NR, not recordable; M, male; SPO, sporadic.

###### 

Clinical and electrophysiological features from 27 IPN index patients with CMT2, for whom a candidate variant was identified

  Patient   Disease    Gene               Gender   Age at onset   Deep tendon reflexes   Foot deformities   Muscular weakness and wasting of distal muscles   Sensory loss   Other clinical signs                                                                                            Median nerve motor MNCV (m/s)   Median nerve distal CMAP (mV)   Nerve biopsy
  --------- ---------- ------------------ -------- -------------- ---------------------- ------------------ ------------------------------------------------- -------------- --------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------- ---------------------------------------------------------
  1         CMT2 AR    *MFN2 GDAP1*       F        6 years        −                      \+                 \+                                                \+                                                                                                                             42                              NA                              Denervation- reinervation
  4         CMT2 AD    *NEFL*             M        9 years        −                      \+                 \+                                                −                                                                                                                              NA                              NA                              --
  7         CMT2 AD    *GAN*              M        68 years       −                      \+                 \+                                                \+             Right ptosis and cerebellar ataxia                                                                              50                              8                               --
  8         CMT2 AR    *MFN2 GDAP1*       M        7 years        NA                     \+                 \+                                                −                                                                                                                              39                              6.7                             --
  11        CMT2 AR    *IGHMBP2*          F        7 years        −                      \+                 \+                                                \+                                                                                                                             39                              NA                              --
  19        CMT2 AR    *GAN*              M        8 years        NA                     \+                 \+                                                \+                                                                                                                             −                               −                               --
  22        CMT2 AD    *AARS*             M        14 years       NA                     NA                 \+                                                −                                                                                                                              52                              7.4                             NA
  23        CMT2 AR    *GDAP1 DCTN1*      F        43 years       −                      \+                 \+                                                \+                                                                                                                             50                              NA                              --
  24        CMT2 AR    *DARS2*            M        8 years        −                      −                  \+                                                \+             Surgery of right ureter                                                                                         42                              2.6                             NA
  26        CMT2 SPO   *MFN2*             M        3 years        NA                     NA                 \+                                                NA                                                                                                                             NA                              NA                              Demyelinating aspect with secondary axonal degeneration
  27        CMT2 AD    *INF2*             F        13 years       −                      \+                 \+                                                \+                                                                                                                             47                              1.99                            --
  29        CMT2 AD    *LRSAM1*           M        15 years       −                      −                  \+                                                \+             Scoliosis                                                                                                       64                              5.5                             --
  31        CMT2 AD    *NEFL*             M        Infancy        −                      \+                 \+                                                \+             Vocal cords palsy                                                                                               48                              NA                              --
  33        CMT2 AD    *KIF1B*            F        30 years       \+                     \+                 \+                                                \+             Scoliosis, Hashimoto disease, erythema nodosum                                                                  60                              NA                              --
  35        CMT2 AD    *INF2*             F        Infancy        −                      −                  \+                                                −              Deafness                                                                                                        47                              1.43                            --
  37        CMT2 AD    *KIF5A*            F        47 years       −                      \+                 \+                                                \+                                                                                                                             43                              NA                              --
  38        CMT2 SPO   *SEPT9 ARHGEF10*   M        Adolescence    −                      \+                 \+                                                \+             Renal cancer                                                                                                    47                              6.5                             --
  42        CMT2 AD    *MFN2*             F        9 years        \+                     \+                 \+                                                −                                                                                                                              62                              7.4                             --
  43        CMT2 AD    *BAG3*             F        7 years        \+                     \+                 \+                                                −              Scoliosis+learning disability+ventricular dilatation+epilepsy                                                   53                              8.9                             --
  44        CMT2 AD    *KIF5A*            M        Adolescence    −                      \+                 \+                                                −                                                                                                                              76                              4.5                             NA
  46        CMT2 AR    *MFN2*             M        3 years        NA                     NA                 \+                                                \+                                                                                                                             48                              0.13                            --
  51        CMT2 AD    *HSPB1*            M        40 years       \+                     \+                 \+                                                \+                                                                                                                             50                              NA                              --
  53        CMT2 AD    *NEFL*             F        Infancy        \+                     \+                 \+                                                −                                                                                                                              58                              1.03                            NA
  54        CMT2 AR    *GAN*              F        2 years        −                      \+                 \+                                                −              Congenital ptosis                                                                                               NA                              NA                              --
  58        CMT2 AD    *BICD2*            F        8 years        \+                     \+                 \+                                                −                                                                                                                              48                              11.4                            --
  59        CMT2 SPO   *SPTLC1*           F        36 years       −                      −                  \+                                                \+             Chronic inflammatory demyelinating polyneuropathy with 140 antineurofasciine Ab+membranous glomerulonephritis   41                              5                               Demyelinating aspect and axonal degeneration
  60        CMT2 AD    *AARS*             M        20 years       NA                     \+                 \+                                                \+                                                                                                                             NA                              NA                              NA

+, presence; −, absence; AD, autosomal dominant; AR, autosomal recessive; CMAP, compound muscle action potential; CMT2, Charcot-Marie-Tooth disease type 2; F, female; IPN, inherited peripheral neuropathy; M, male; MNCV, motor nerve conduction velocity; NA, not available; SPO, sporadic.

###### 

Clinical and electrophysiological features from 14 IPN index patients with hereditary sensory and autonomic neuropathy (HSAN), distal hereditary motor neuropathy (dHMN) and intermediate CMT, for whom a candidate variant was identified

  Patient   Disease        Gene             Gender   Age at onset   Deep tendon reflexes   Foot deformities   Muscular weakness and wasting of distal muscles   Sensory loss   Other clinical signs           Median nerve motor MNCV (m/s)   Median nerve distal CMAP (mV)   Median nerve sensitive (m/s)   Nerve biopsy
  --------- -------------- ---------------- -------- -------------- ---------------------- ------------------ ------------------------------------------------- -------------- ------------------------------ ------------------------------- ------------------------------- ------------------------------ --------------
  6         dHMN AD        *TRPV4*          M        2 years        \+                     \+                 \+                                                −              Scoliosis                      Normal                          NA                              NA                             --
  30        dHMN AR        *SPG11*          M        19 years       −                      NA                 \+                                                −                                             NA                              NA                              NA                             NA
  39        dHMN AD        *REEP1*          F        33 years       \+                     \+                 \+                                                −              Dysphagia                      NA                              NA                              NA                             NA
  55        dHMN SPO       *DYNC1H1*        F        12 years       NA                     −                  \+                                                −                                             NA                              NA                              NA                             NA
  57        dHMN SPO       *MYH14*          M        50 years       −                      \+                 \+                                                −              Scoliosis                      67                              NA                              NA                             --
  13        HSAN AD        *SPTLC2 HSPB3*   M        24 years       −                      \+                 \+                                                \+                                            NA                              NA                              NA                             --
  25        HSAN AD        *NEFL*           F        20 years       −                      −                  −                                                 \+                                            46                              9.79                            38                             --
  48        HSAN AR        *FAM134B*        F        12 years       −                      \+                 \+                                                \+             Ulcero-mutilating neuropathy   NA                              NA                              NA                             NA
  49        HSAN AD        *HSPB1*          M        49 years       NA                     −                  −                                                 \+             Sensorineural hearing loss     49                              9.2                             31                             --
  56        HSAN AD        *SPTLC2 MYH14*   M        10 years       NA                     −                  −                                                 \+             Neurological pain              NA                              NA                              NA                             NA
  36        CMT inter AD   *DNM2*           M        41 years       −                      \+                 NA                                                NA                                            54                              3.6                             NA                             Fibre loss
  40        CMT inter AD   *KIF5A*          F        53 years       \+                     \+                 \+                                                −                                             48,9                            NA                              NA                             --
  50        CMT inter AD   *YARS*           M        14 years       \+                     \+                 \+                                                \+                                            34                              2.2                             NA                             Axonal loss
  52        CMT inter AD   *INF2*           F        NR             NA                     NA                 NA                                                NA                                            NA                              NA                              NA                             NA

+, presence; −, absence; AD, autosomal dominant; AR, autosomal recessive; CMAP, compound muscle action potential; CMT, Charcot-Marie-Tooth disease; F, female; M, male; MNCV, motor nerve conduction velocity; NA, not available; SPO, sporadic.

The average depth obtained in our panel of 81 genes was 196X and the average coverage at 20X was 98%, with a weaker coverage at 20X for *SOX10*, *INF2* and *CTDP1* genes (81%, 86% and 86% respectively).

Through targeted NGS of 81 IPN genes (see online [supplementary table 1](#SP1){ref-type="supplementary-material"}), we found one or several potentially pathogenic variants in 60 patients from our cohort of 123 index cases, thereby defining a success rate of 49%. The average age was 20 for positive cases, while it was significantly higher (45 years old) for negative cases.

More precisely, we found a pathogenic variant for 49 patients (40%) and a potentially pathogenic variant for 11 patients (9%). Thirty-seven per cent of cases showed a recessive transmission and 63% a dominant transmission. Twenty-six variants were reported in the literature, whereas 52 variants were never reported. Among these 52 new variants, we were able to confirm the pathogenicity of 25, based on: (1) their low frequency in the ExAC database, (2) compatible phenotype, (3) segregation in the family study and (4) in silico pathogeneicity prediction. However, we were unable to establish the pathogenicity in 11 patients requiring further explorations at either clinical or genetic levels (see [table 2A,B](#T2){ref-type="table"}).

###### 

Known mutations identified in 81 IPN genes by next-generation sequencing

  Patient   Disease classification   Inheritance   Gene             Haplotype   cDNA change                             Amino acid change                   ACMG classification   Report
  --------- ------------------------ ------------- ---------------- ----------- --------------------------------------- ----------------------------------- --------------------- ----------------------------------------------
  2         CMT1                     AR            *SH3TC2*         comp het    c.\[211C\>T\];\[2860C\>T\]              p.\[Gln71\*\];\[Arg954\*\]          P/P                   Senderek *et al* [@R25]
  3         CMT1                     SPO           *GJB1*           het         c.223C\>T                               p.Arg75Trp                          P                     Silander *et al* [@R26]
  6         HMN                      AD            *TRPV4*          het         c.806G\>A                               p.Arg269His                         P                     Landouré *et al* [@R27]
  8         CMT2                     AR            *MFN2 GDAP1*     het         c.707C\>T c.473C\>T                     p.Thr236Met p.Thr158Ile             PP PP                 Kijima *et al* [@R28]
  9         CMT1                     AD            *DNM2*           het         c.1597G\>A                              p.Gly533Ser                         PP                    Fabrizi *et al* [@R29]
  10        CMT1                     AD            *NEFL*           het         c.1319 C\>T                             p.Pro440Leu                         PP                    Benedetti *et al* [@R30]
  11        CMT2                     AR            *IGHMBP2*        comp het    c.\[2368C\>T\];\[2911_2912delAG\]       p.\[Arg790\*\];\[Arg971Glufs4\*\]   P/P                   Maystadt *et al* [@R31]
  15        CMT1                     AD            *LITAF*          het         c.334G\>A                               p.Gly112Ser                         P                     Street *et al* [@R32]
  17        CMT1                     AR            *GDAP1*          hoz         c.786_786delG                           p.Phe263Leufs\*22                   P                     Nelis *et al* [@R33]
  18        CMT1                     AD            *AARS*           het         c.986G\>A                               p.Arg329His                         P                     Latour *et al* [@R34]
  20        CMT1                     AR            *FIG4*           comp het    c.\[122T\>C\];\[830_837delGTAAATTT\]    p.\[Ile41Thr\];\[Lys278Trpfs\*6\]   PP/P                  Chow *et al* [@R35]
  23        CMT2                     AR            *GDAP1 DCTN1*    het         c.358C\>T c.2384G\>A                    p.Arg120Trp p.Arg795His             P PP                  Pedrola *et al*,[@R36] Sivera *et al* [@R37]
  28        CMT1                     AD            *LITAF DCTN1*    het         c.334G\>A c.875G\>A                     p.Gly112Ser p.Arg292His             PP VUS                Street *et al* [@R32]
  31        CMT2                     AD            *NEFL*           het         c.803T\>G                               p.Leu268Arg                         PP                    Fabrizi *et al* [@R38]
  32        CMT1                     SPO           *NEFL*           het         c.293A\>G                               p.Asn98Ser                          PP                    Yoshihara *et al* [@R39]
  41        CMT1                     AR            *SH3TC2*         hoz         c.3325 C\>T                             p.Arg1109\*                         P                     Gooding *et al* [@R40]
  42        CMT2                     AD            *MFN2*           het         c.311G\>T                               p.Arg104Leu                         P                     Sitarz *et al* [@R41]
  43        CMT2                     AD            *BAG3*           het         c.343C\>T                               p.Pro115Ser                         PP                    Villard *et al*,[@R42] Selcen *et al* [@R43]
  47        CMT1                     AR            *HK1*            comp het    c.(1--22124G\>C\];\[c.1--20809 G\>A\]                                       PP/PP                 Hantke *et al* [@R44]
  51        CMT2                     AD            *HSPB1*          het         c.523C\>T                               p.Gln175\*                          P                     Rossor *et al* [@R45]
  53        CMT2                     AD            *NEFL*           het         c.998T\>C                               p.Leu333Pro                         PP                    Choi *et al* [@R46]
  54        CMT2                     AR            *GAN*            comp het    c.\[1429C\>T\];\[1724T\>C\]             p.\[Arg477\*\];\[Ile575Thr\]        P/VUS                 Bomont *et al* [@R47]
  56        HSAN                     AD            *SPTLC2 MYH14*   het         c.547 C\>T c.71C\>G                     p.Arg183Trp p.Ala24Gly              PP VUS                Suriyanarayanan *et al* [@R48]
  60        CMT2                     AD            *AARS*           het         c.986G\>A                               p.Arg329His                         P                     Latour *et al* [@R34]

AD, autosomal dominant; AR, autosomal recessive; CMT1, Charcot-Marie-Tooth disease type 1; CMT2, Charcot-Marie-Tooth disease type 2; comp het, compound heterozygous; het, heterozygous; HMN, hereditary motor neuropathy; hoz, homozygous; HSAN, hereditary sensory and autonomic neuropathy; IPN, inherited peripheral neuropathy; P, pathogenic; PP, probably pathogenic; SPO, sporadic; VUS, variant of unknown significance.

###### 

Novel pathogenic sequence variations identified in IPN genes by next-generation sequencing

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Disease classification   Inheritance   Gene                   Haplotype   cDNA change                     Amino acid change                      ACMG          ExAC                   Mutation\    Polyphen-2                        UMD-Predictor               PhyloP
                                                                                                                                                                                                  Taster                                                                     
  --------- ------------------------ ------------- ---------------------- ----------- ------------------------------- -------------------------------------- ------------- ---------------------- ------------ --------------------------------- --------------------------- ---------------------------
  1         CMT2                     AR            *MFN2 GDAP1*           het         c.311G\>A c.400delG             p.Arg104Gln p.Asp134Metfs13            PP P          NA NA                  D1 NA        1 PD NA                           100 P NA                    5,37 HC NA

  5         CMT1                     SPO           *INF2*                 het         c.311G\>A                       p.Cys104Tyr                            PP            NA                     D1           NA                                NA                          5,69 HC

  7         CMT2                     AD            *GAN*                  het         c.862C\>G                       p.Pro288Ala                            PP            NA                     D1           0,001 B                           NA                          2,95 MC

  13        HSAN                     AD            *SPTLC2 (HSPB3)*       het         c.1304G\>T (c.246_246delT)      p.Gly435Val (p.Glu83Lysfs\*13)         PP VUS        NA 5\*10--5            D1 NA        1 PD NA                           78 P NA                     6,18 HC NA

  14        CMT1                     AR            *SH3TC2*               comp.het    c.\[224G\>C\];\                 p.\[Arg75Pro\];\                       PP/PP         NA/NA                  D1/D1        1 PD/0999 PD                      81 P/ 84 P                  3,43 MC 4,81 HC
                                                                                      \[3377T\>C\]                    \[Leu1126Pro\]                                                                                                                                         

  19        CMT2                     AR            *GAN*                  hoz         c.890C\>T                       p.Pro297Leu                            PP            NA                     D1           0,906 Possibdam                   NA                          5,86 HC

  22        CMT2                     AD            *AARS*                 het         c.525C\>G                       p.Phe175Leu                            PP            1/121242               D1           1 PD                              96 P                        2,22 MC

  24        CMT2                     AR            *DARS2*                comp.het    c.\[74_74delT(;)713C\>T\]       p.\[Ile25fs\*38(;)\                    P/VUS         2/\                    D1/NA        0,959 PD/NA                       93 P/ NA                    0,85 WC NA
                                                                                                                      Ser238Phe\]                                          121358/NA                                                                                         

  26        CMT2                     SPO           *MFN2*                 het         c.1127T\>G                      p.Met376Arg                            PP            NA                     D1           0,984 PD                          96 P                        4,48 HC

  29        CMT2                     AD            *LRSAM1*               het         c.2138_2139delT                 p.Ile713Thrfs\*22                      P             NA                     NA           NA                                NA                          NA

  30        HMN                      AR            *SPG11*                comp.het    c.\[31G\>C\];\                  p.\[Ala11Pro\];\                       PP/VUS        6/121316 5/57750       D1/Poly      0,808 Possibdam 0,899 Possibdam   84 P/ 44 Poly               2,14 MC 0,04 WC
                                                                                      \[6167A\>T\]                    \[Glu2056Val\]                                                                                                                                         

  33        CMT2                     AD            *KIF1B*                het         c.2086C\>G                      p.His696Asp                            PP            NA                     D1           0,978 PD                          81 P                        5,61 HC

  34        CMT                      SPO           *KIF1B*                het         c.2030G\>A                      p.Ser677Asn                            PP            NA                     D1           1 PD                              78 P                        1,044 WC

  36        CMT inter                AD            *DNM2*                 het         c.1352G\>T                      p.Arg451Leu                            PP            NA                     D1           NA                                93 P                        3,68 MC

  37        CMT2                     AD            *KIF5A*                het         c.395A\>G                       p.Lys132Arg                            PP            NA                     D1           1 PD                              78 P                        1,088 WC

  39        HMN                      AD            *REEP1*                het         c.568G\>A                       p.Gly190Ser                            PP            3/119252               0,999 Poly   0,148 B                           63ProbPoly                  0,61 WC

  40        CMT inter                AD            *KIF5A*                het         c.854C\>T                       p.Thr285Ile                            PP            NA                     D1           1 PD                              93 P                        5,29 HC

  44        CMT2                     AD            *KIF5A*                het         c.332G\>C                       p.Arg111Pro                            PP            NA                     D1           1 PD                              96 P                        5,61 HC

  45        CMT1                     AD            *INF2*                 het         c.314 T\>G                      p.Val105Gly                            PP            NA                     D1           1 PD                              90 P                        3,11 MC

  46        CMT2                     AR            *MFN2*                 comp.het    c.\[1714C\>T\];\                p.\[Gln572Glu\];\                      PP/PP         1/246228\              D1/D1        0,073 B /\                        100 P 100 P                 5,13 HC 4,08 MC
                                                                                      \[1928T\>C\]                    \[Leu643Pro\]                                        1/246238                            0,983 PD                                                      

  48        HSAN                     AR            *FAM134B*              hoz         c.896-897delAA                  p.Lys299Argfs\*6                       P             1/1 20 334             NA           NA                                NA                          NA

  55        HMN                      SPO           *DYNC1H1*              het         c.5578C\>A                      p.Gln1860Lys                           PP            NA                     D1           0,001 B                           75 P                        6,34 HC

  57        HMN                      SPO           *MYH14*                het         c.4517G\>T                      p.Arg1506Leu                           PP            NA                     0,929 D      0,987 PD                          81 P                        2,95 MC

  58        CMT2                     AD            *BICD2*                het         c.2042C\>T                      p.Ser681Leu                            PP            NA                     D1           1 PD                              90 P                        5,61 HC

  59        CMT2                     SPO           *SPTLC1*               het         c.451C\>T                       p.Arg151Cys                            PP            2/118640               D1           0,264 B                           100 P                       4,00 MC

  4         CMT2                     AD            *NEFL*                 het         c.67C\>G                        p.Arg23Gly                             VUS           NA                     NA           NA                                NA                          2,09 WC

  12        CMT1                     AD            *LMNA*                 het         c.1694A\>T                      p.His565Leu                            PP            NA                     NA           NA                                84 P                        2,30 MC

  16        CMT1                     AD            *GJB1*                 het         c.830G\>A                       p.Ser277Asn                            PB            2/26732                0,876 Poly   0,002 B                           63 ProbPoly                 2,38 MC

  21        CMT1                     AD            *TRPV4 KIF1B LRSAM1*   het         c.812G\>A\                      p.Arg271His p.Tyr1117Cys p.Gln553Pro   VUS VUS VUS   1/120838 1/120270 NA   D1 Poly D1   0,764 Possibdam 0 B 0,994 PD      78 P NA 93 P                5,13 HC - 1,57 NC 3,60 MC
                                                                                      c.3350A\>G\                                                                                                                                                                            
                                                                                      c.1658A\>C                                                                                                                                                                             

  25        HSAN                     AD            *NEFL*                 het         c.995_997delAGC                 p.Gln332del                            P             NA                     NA           NA                                NA                          NA

  27        CMT2                     AD            *INF2*                 het         c.2709G\>C                      p.Gln903His                            VUS           1/119080               D 0,991      0,998 PD                          57 ProbPoly                 2,47 MC

  35        CMT2                     AD            *INF2*                 het         c.3637C\>T                      p.Arg1213Trp                           VUS           2/61282                Poly         0,998 PD                          72 ProbPatho                1,66 WC

  38        CMT2                     SPO           *SEPT9 ARHGEF10*       het         c.53G\>A c.3289A\>G             p.Arg18Thr p.Ile1097Val                VUS VUS       1/118806 1/120124      Poly Poly    0,015 B 0,023 B                   69 ProbPatho 66 ProbPatho   0,28 NC 0,04 WC

  49        HSAN                     AD            *HSPB1*                het         c.224G\>A                       p.Arg75His                             VUS           NA                     D1           0,539 Possibdam                   54 ProbPoly                 2,38 MC

  50        CMT inter                AD            *YARS*                 het         c.710G\>A                       p.Arg237Gln                            VUS           3/121190               0,983 D      0,018 B                           78 P                        2,47 MC

  52        CMT inter                AD            *INF2*                 het         c.2459G\>A                      p.Arg820Gln                            VUS           NA                     Poly         0,001 B                           39 Poly                     −0,68 NC

  61        CMT1                     SPO           *FGD4*                             Duplication of exons 3 to 14    Not described in conrad.hg19                                                                                                                           

  62        CMT2                     AR            *TFG*                              Duplication of exons 2 and 3    Not described in conrad.hg19                                                                                                                           

  28        CMT2                     AD            *TFG*                              Sequence variation in\          Not described in conrad.hg19                                                                                                                           
                                                                                      LITAF and DCTN1\                                                                                                                                                                       
                                                                                      +duplication of exons 2 and 3                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, autosomal dominant; AR, autosomal recessive; B, benign; CMT1, Charcot-Marie-Tooth disease type 1; CMT2, Charcot-Marie-Tooth disease type 2; comp het, compound heterozygous; comp het, composite heterozygosis; D1, disease causing; HC, highly conserved; het, heterozygous; hoz, homozygous; HSAN, hereditary sensory and autonomic neuropathy; IPN, inherited peripheral neuropathy; MC, moderately conserved; NA, not available; NT, not conserved; P, pathogenic; Poly, polymorphism; Possibdam, possibly damaging; PB, probably benign; PD, probably damaging; PP, probably pathogenic; ProbPoly, probably polymorphism; ProbPatho, probably pathogenic; SPO, sporadic; VUS, variant of unknown significance; WC, weakly conserved.

Among the 28 patients affected with demyelinating forms, 16 (57%) had a pathogenic variant, 3 (11%) had a potentially pathogenic variant and 9 (32%) remained negative. The most frequently mutated gene was *SH3TC2* responsible for CMT4C with five variants found, of which two were not reported in the literature. The other mutations were found in the following genes: *NEFL* (2), *FIG4* (2), *KIF1B* (2), *HK1* (2), *INF2* (2), *LITAF/SIMPLE* (2), *DNM2* (1), *LMNA* (1), *DCTN1* (1), *GJB1* (2), *GDAP1* (1), *TRPV4* (1), *AARS (1)* and *LRSAM1* (1).

Among the 64 patients with axonal forms, 23 (36%) had a pathogenic variant, 4 (6%) had a potentially pathogenic variant and 37 (58%) remained negative. The most frequently mutated gene was *MFN2* with six variants found, of which two were not reported in the literature, then *GAN* with four variants found, of which two were not reported, and then the following genes: *NEFL* (3), *GDAP1* (3), *AARS* (2), *IGHMBP2* (2), *DCTN1* (1), *DARS2* (2), *KIF5A* (2), *INF2* (2), *LRSAM1* (1), *KIF1B* (1), *SETP9* (1), *ARHGEF10* (1), *HSPB1* (1), *SPTLC1* (1), *BAG3* (1) and *BICD2* (1).

Among the 11 patients who had dHMN, 5 (45%) had a pathogenic variant and 6 (55%) remained negative. The most frequently mutated gene was *SPG11* with two variants found not described in the literature, and then *DYNC1H1* (1), *TRPV4* (1), *REEP1* (1) and *MYH14* (1).

Among the nine patients who had HSAN, three (33%) had a pathogenic variant, two (22%) had a potentially pathogenic variant and four (45%) remained negative. *SPTLC2* was the most frequently mutated gene with two variants found, of which one was not reported. Only one variant was reported in the following genes: *FAM134B, HSPB1* and *NEFL*.

Among the eight patients who had intermediate CMT, two (25%) had a pathogenic variant, two (25%) had a potentially pathogenic variant and four (50%) remained negative. A potentially pathogenic variant was found in genes: *DNM2, KIF5A, YARS* and *INF2*.

Overall, the most frequently mutated genes were (by decreasing order) (see [figure 1](#F1){ref-type="fig"}): *MFN2* (7.7%), *SH3TC2* (6.4%), *NEFL* (5.1%), *GDAP1* (5.1%) and *GAN* (5.1%). Then come the following genes : *AARS* (3.8%), *KIF5A* (3.8%), *KIF1B* (2.6%), *INF2* (2.6%), *DARS2* (2.6%), *DCTN1* (2.6%), *DNM2* (2.6%), FIG4 (2.6%), *HK1* (2.6%), *IGHMBP2* (2.6%), *LITAF* (2.6%), *SPG11* (2.6%), *SPTLC2* (2.6%), *MYH14* (2.6%), *GJB1* (1.3%), *HSPB1* (1.3%), *TRPV4* (1.3%), *LRSAM1* (1.3%), *BICD2* (1.3%), *SPTLC1* (1.3%), *REEP1* (1.3%), *HSPB3* (1.3%), *FAM134B* (1.3%), *DYNC1H1* (1.3%) and *BAG3* (1.3%).

![Frequency of mutations in each gene identified in our cohort of 123 patients.](bmjopen-2018-021632f01){#F1}

In our laboratory, before the advent of targeted NGS, 20 genes responsible for IPN were explored by Sanger sequencing : *MPZ*, *PMP22*, *PRX*, *EGR2*, *MTMR2*, *NDRG1*, *HSPB1*, *HSPB8*, *BSCL2*, *FGD4*, *LMNA*, *LITAF*, *TRPV4*, *GJB1*, *SH3TC2*, *HK1*, *GDAP1*, *SPTLC1*, *SPTLC2* and *MFN2*. The duplication of *PMP22* responsible for CMT1A was tested by MLPA.

Between 2012 and 2014, 102 patients with IPN were analysed through Sanger sequencing and MLPA. Ninety patients had CMT1 and 12 patients had CMT2. 46/102 (45%) patients had a duplication of *PMP22*. The remaining 56 patients were analysed by Sanger sequencing of candidate genes. A mutation was found in 13 patients (23% of positive cases): four mutations in *MPZ*, four mutations in *GJB1*, two mutations in *GDAP1*, two mutations in *MFN2* and one mutation in *HK1*. Out of the 44 patients with CMT1, we achieved the molecular diagnosis in 25% of them, while only 2 out of 12 patients with CMT2 (17%) could be ascertained. Among the remaining 43 negative cases, 17 were analysed by targeted analysis of 81 genes from NGS data and for 10 of these 17 patients, we identified the molecular defect in a gene unexplored by Sanger sequencing.

Between 2015 and 2017, a pathogenic variant was found in 49 patients (40%) by targeted analysis of 81 genes from NGS data. During the same period, the *PMP22* duplication was identified by MLPA in 67 patients.

In conclusion, in our laboratory, we were able to reach a diagnosis in 23% of patients using Sanger sequencing and in 40% of patients when using targeted NGS of 81 IPN genes. When including *PMP22* duplication, 63% of patients with CMT1 were able to get a diagnosis with Sanger analysis against 87% with NGS. In parallel, we were able to make a diagnosis for 17% of CMT2 patients with Sanger analysis against 36% with NGS.

Our comparative statistical analysis allows us to conclude that the molecular diagnosis yield by targeted NGS was two times higher than molecular diagnosis by Sanger sequencing (OR=2.18, p=0.04, (1.0224; 4.8954)).

We compared the solve rate between sporadic cases and family cases. Within our cohort of 123 patients, 42 were sporadic cases; we found a potentially pathogenic variant in 8 of them (19%). Conversely, 51 were familial cases following an autosomal inheritance mode, 25 patients (49%) were able to have a molecular diagnosis.

One of the other objectives of this study was to search for CNVs in our cohort. We found one triplication and one duplication in *FGD4* and *TFG* genes in two patients with CMT1 and CMT2, respectively, as well as a duplication in one of the 81 genes in patient 28 for whom we also found two heterozygous variants in *LITAF* and *DCTN1* using targeted NGS (see [table 2B](#T2){ref-type="table"}). Overall, ExomeDepth and Q-PCR enabled us to make a potential molecular diagnosis for two additional patients and consequently raise our percentage of diagnosis to 41%.

Discussion {#s8}
==========

Before targeted NGS, a strategy of sequential molecular diagnosis through Sanger sequencing was implemented. Genes to be screened were chosen according to phenotype, inheritance and electrophysiological criteria. Therefore, the strategy relied mainly on genotype--phenotype correlation. Targeted NGS allows for a more comprehensive analysis with broader panels of genes, faster and cost-effective outcomes.[@R13]

In our laboratory, we chose targeted NGS in order to avoid the interpretation of numerous variants generated with other NGS strategy, such as whole exome sequencing (WES) or whole genome sequencing, in particular when only one individual is available in the same family.

The use of NGS allowed us to raise our rate of molecular diagnosis to 87% for CMT1% and 36% for CMT2. The high success rate obtained for CMT1 with NGS is due to the high prevalence of *PMP22* duplication in this disease subgroup. The *PMP22* duplication is responsible for CMT1A, the most frequent CMT subtype, accounting for 48.8% to 63.2% of all subtypes.[@R15] Several publications have shown that mutations in *GJB1*, *MFN2*, *MPZ* and *PMP22* account for 80 to 94.9% of CMT, and recommended to first complete targeted Sanger sequencing based on clinical phenotype. *MFN2* was the most frequently mutated gene found among our cohort of 64 patients with CMT2. NGS enabled us to find a high frequency of pathogenic variants in *NEFL*, *GAN*, *AARS* and *KIF5A*. These were less frequent and we would not have explored them as first line. Other variants found in *BAG3*, *BICD2*, *DYNC1H1*, *REEP1* and *FAM134B* are much more rare. A survey of 17 880 patients with CMT compared the diagnosis outcomes of Sanger-MLPA and NGS-MLPA[@R17] analyses. This study suggested that the frequency of positive results for 14 CMT genes was not significantly different (p\<0.05) in spite of differences in testing strategies between Sanger and NGS. But the bias of this survey is that it compared the same genes in the two groups.

In our cohort of 123 patients, NGS enabled us to make a positive molecular diagnosis of point mutation (single-nucleotide variation (SNV)) for 49 patients (40%) while saving considerable time and cost. This result is consistent with those found in previous studies, including Hartley *et al*,[@R18] who were able to make a molecular diagnosis by WES in 12 patients (24%) in a cohort of 50 families with IPN. Similarly, Gonzaga-Jauregui *et al* [@R4] was able to make a molecular diagnosis in 17 patients (46%) by WES in a cohort of 37 families with CMT.

Recently, Dorhn and collaborators[@R19] describe a cohort of 612 subjects who came from Germany affected by IPN and found a majority of point mutation in *MPZ*, *MFN2*, *GJB1* and *SH3TC2*. Our study describes patients who came from the south of France and found a majority of mutation in *MFN2*, *SH3TC2*, *NEFL*, *GAN*, *GDAP1*, *AARS* and *KIF5A.* In fact, our cohort is composed of people who came from the Mediterranean region which probably explains the different spectrum delineation of our study, notably the relatively high frequency of *GAN* variants.

Moreover, 11 patients in our cohort were undiagnosed but we found a potentially pathogenic variant without confirmation of pathogenicity. In the following, we will detail some cases of particular interest.

Boyer and collaborators[@R20] have described nine mutations in *INF2* in 12 patients with CMT with focal segmental glomerulosclerosis. In our study, patients 5, 27, 35, 45 and 52 have a sequence variation in this gene and, to date, no nephrological disease is known in these patients. Patients 5 and 45 have a probably pathogenic variant according to Richards classification. Those mutations are located in the same codon that patient described by Boyer. While patient 27, 35 and 52 have a VUS according to Richards classification. At that time, without nephrological examination and familial study, we were not able to exclude those variants.

We have two patients in this cohort affected by CMT1 (patient 21) and CMT2 (patient 38) carrying numerous variants in potential genes. We found three VUS in *TRPV4* (CMT2C), *LRSAM1* (CMT2P) and *KIF1B* (CMT2A1) genes for patient 21. Mutations in these three genes were reported to be in relation with CMT type 2 or dHMN. In that case, we have too much variant which could explain patient's phenotype at isolated state or in association. A familial study is indicated. Patient 38 showed two VUS in *SEPT9* (hereditary neuralgic amyotrophy)[@R21] and *ARHGEF10* (slowed nerve conduction velocity).[@R22] These mutations could thus separately or in association explain these patient's phenotype. Unfortunately, the family study could not be achieved and we could not make any conclusions related to the contribution of these variants in the disease.

Only one variant was classified as probably benign in Richards classification, and namely variant c.830G\>A in *GJB1* which was identified in patient 16 suffering from autosomal-dominant CMT1 with first clinical manifestations at the age of 15. She presents a severe phenotype with standard clinical signs of peripheral motor and sensory neuropathy. Motor nerve conduction velocity was 36 m/s in the electromyogram and the nerve biopsy showed Schwann cell proliferation in the form of an onion bulb. The segregation analysis found this variant in the asymptomatic mother. Her mother could have an inactivation of the mutant allele on one of the X-chromosomes, thus only expresses wild-type Cx32 from the normal allele. NGS analysis did not enable us to identify another potential variant responsible for her neuropathy. Patient 4, affected with autosomal-dominant CMT2, showed severe clinical signs at the age of 9. We found a VUS c.67C\>G, (p.Arg23Gly) in *NEFL* (CMT1F, CMT2E). The segregation analysis found this one in the asymptomatic mother. This case can maybe illustrate incomplete penetrance for this mutation in this family. Alternatively, the disease, in this patient, is due to another mutation in a gene not explored in this targeted NGS.

Patients 13 and 56 are affected with HSAN and carry a mutation in *SPTLC2*, known to be responsible for HSAN1C (MIM 613640). They also have a VUS (according to Richards classification) in another gene. One in *HSPB3* (HMN2C, MIM 613376) for patient 13 and the second one in *MYH14* (peripheral neuropathy, myopathy, hoarseness and hearing loss, MIM 614369) for patient 56. These two patients have perforating ulcers of the foot, hypoaesthesia at sock level but their motor picture also included a severe progressive motor deficiency, severe wasting, contractures and neuropathic pain. In these cases, *SPTLC2* could alone be responsible for the patient's phenotype and we can consider *HSPB3* and *MYH14* as modifiers or modulators factors likely to account for the motor phenotype of these two patients. In comparison, Sinkiewicz-Darol's team[@R23] showed that the presence of a variant p.Ile92Val in gene *LITAF/SIMPLE* of patients who presented with a duplication or deletion of *PMP22* was linked with an earlier onset of CMT1A or Hereditary Neuropathy by Hypersensibility to Pressure Palsie (HNPP) and could be considered as a modifier. These additional variants could contribute to the variability of the clinical phenotype expression.

Even if the majority of IPNs are explained by SNV, CNV may equally be a genetic cause of IPN and, thanks to NGS strategy, we can now detect these two types of variations. We found three CNVs in three patients, that is, 2.4% in our cohort. In comparison, Pfundt's team[@R24] looked for CNVs with the coNIFER software using reading depth data with exome high-throughput sequencing in a cohort of 2603 patients who had different genetic pathologies. In the group with neurodevelopment disorders, muscular disorders and abnormal coordination, they respectively found 1.3%, 0.6% and 0.9% of CNV. We found a higher percentage of CNVs in our IPN group (none significant Fisher's exact test). This study of CNV enabled us to raise our rate of molecular diagnosis to 51 patients (41%) out of a cohort of 123 patients.

Targeted NGS allows us to improve our molecular diagnosis in IPN and allows an accurate genetic counselling in families. Moreover, a positive molecular diagnosis is the first step to participate in clinical trials.

Conclusion {#s9}
==========

In our laboratory, NGS improved the molecular diagnostic rate, allowing for 40% of the patients suffering from IPN. Eighty-seven per cent of patients with CMT1 can now get a precise molecular diagnosis. On the other hand, 64% of CMT2 cases remain unsolved. Indeed, numerous aetiologies of neuropathies are found in elderly patients, such as diabetic, inflammatory, alcoholic, idiopathic and autoimmune neuropathies and may be confused with hereditary neuropathies. Most importantly, NGS analysis allows to describe novel mutations, not yet reported in the literature, that are of significant importance for the scientific and medical community. Moreover, the analysis of NGS data enabled us to detect possible duplications and deletions of genes not investigated routinely. Targeted NGS with a panel of 81 genes is therefore well adapted to IPN molecular diagnosis. However, the generation of many variants of unknown significance requires a collegial interpretation by biologists, geneticists and neurologists.
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